Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase results from a single-group, phase 2, open-label study
Annals of Internal Medicine Feb 24, 2018
Mahon FX, et al. - The objective herein was to analyze the treatment-free remission (TFR) after discontinuation of second-line nilotinib therapy in the treatment of chronic myeloid leukemia (CML). Data illustrated that TFR was possibly achievable in patients with sustained MR4.5 after switching to nilotinib.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
